雅虎香港 搜尋

搜尋結果

1. www.webnewswire.com › 2024/03/30 › japan-eisai-to-divestJapan – Eisai to Divest Rights for Merislon and Myonal in Ja ...

   www.webnewswire.com › 2024/03/30 › japan-eisai-to-divest

   • 網頁紀錄

   2024年3月30日 · Mar 30, 2024 | Business. Eisai Co., Ltd. announced today that it has entered into an agreement to divest its rights for vertigo and equilibrium disturbance treatment Merislon® (generic name: betahistine mesilate) and muscle relaxant Myonal® (generic name: eperisone hydrochloride) in Japan to Kaken Pharmaceutical Co., Ltd.

2. www.pharmajournalist.com › eisai-to-divest-rights-forEisai to Divest Rights for Merislon and Myonal in Japan to K ...

   www.pharmajournalist.com › eisai-to-divest-rights-for

   • 網頁紀錄

   2024年4月1日 · On Apr 1, 2024. Eisai Co., Ltd. announced that it has entered into an agreement to divest its rights for vertigo and equilibrium disturbance treatment Merislon (generic name: betahistine mesilate) and muscle relaxant Myonal (generic name: eperisone hydrochloride) in Japan to Kaken Pharmaceutical Co., Ltd.

3. en.acnnewswire.com › press-release › englishEisai: Research on Treatments for Alzheimer's Disease ...

   en.acnnewswire.com › press-release › english

   • 網頁紀錄

   2024年4月18日 · TOKYO, Apr 18, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that “The Research on Treatments for Alzheimer’s Disease Based on its Pathological Mechanisms” has received the Award for Science and Technology (Research Category) as a part of the FY2024 Commendation for Science and Technology by the Minister of Education, Culture, Sports, ...

4. www.jcnnewswire.com › english › CompanyNewsEisai

   www.jcnnewswire.com › english › CompanyNews

   • 網頁紀錄

   2024年4月1日 · Eisai Co., Ltd. announced today that it has entered into an agreement to divest its rights for vertigo and equilibrium disturbance treatment Merislon (generic name: betahistine mesilate) and muscle relaxant Myonal (generic name: eperisone hydrochloride) in Japan

5. www.drugoffice.gov.hk › eps › drugDrug Office | 藥 物 辦 公 室

   www.drugoffice.gov.hk › eps › drug

   • 網頁紀錄

   2024年4月12日 · MERISLON TAB 6MG Registration No.: HK-48603 Certificate Holder: EISAI (HONG KONG) CO LTD Certificate Holder Address: FLAT/RM D, 18/F, LEE & MAN 169 ELECTRIC ROAD, NORTH POINT, HONG KONG : Part 1 ...

6. www.pharmaceutical-technology.com › news › eisai-divest-rightsEisai signs agreement to divest rights for two therapies to ...

   www.pharmaceutical-technology.com › news › eisai-divest-rights

   • 網頁紀錄

   2024年4月2日 · Eisai will continue to focus on creating and delivering products to target disease. Credit: mkfilm/Shutterstock.com. Eisai has signed an agreement for the divestiture of rights for Merislon and Myonal, two of its long-standing products in Japan, to Kaken Pharmaceutical. The transaction is valued at Y3.8bn ($25.10m).

7. www.jcnnewswire.com › pressrelease › 64853エーザイ、自社創製の新規不眠症治療薬「DAYVIGO(R)」（一般名： ...

   www.jcnnewswire.com › pressrelease › 64853

   • 網頁紀錄

   2024年4月3日 · アジア地域における本剤の最初の承認. 東京, 2021年03月02日 - (JCN Newswire) - エーザイ株式会社（本社：東京都、代表執行役CEO：内藤晴夫）は、このたび、当社の香港の医薬品販売子会社であるEisai（Hong Kong）Co., Ltd.が、自社創製のオレキシン受容体拮抗薬「Dayvigo (R)」（一般名：レンボレキサント、日本製品名：「デエビゴ (R)」）について、「入眠困難、睡眠維持困難のいずれかまたはその両方を伴う成人の不眠症」の適応で新薬承認を取得しましたのでお知らせします。 本承認は、アジア地域（日本を除く）における本剤の最初の承認となります。